All Times Listed in EST

8:00 am Virtual Coffee & Registration

8:50 am Chair’s Opening Remarks

Implemention Lessons Learned from the Lockdown

9:00 am Fireside Chat – Implications of FDA Guidance to Ease Regulatory Enforcement During COVID-19


• As the FDA opens up to mental health in response to COVID-19, waiving restrictions around digital tools for psychiatric disorders, what are the implications and what does this mean long-term?

9:45 am Panel Discussion – The Continued Rise of Digital Therapeutics Post COVID-19

  • Anand Iyer Chief Strategy Officer, WellDoc
  • Frank Baitman Global Head of Compliance & Strategy, Digital Health Technologies, Personalized Healthcare Product Development, Genentech
  • Joris Van Dam Head of Digital Therapeutics, Novartis
  • Jin Lee Director of Digital Health Product/Commercial Strategy, Astellas Pharma
  • Austin Speier Chief Strategy Officer, Click Therapeutics


• What does the pandemic mean for DTx?
• Showing its true potential – Why DTx data is taking centre stage
• As DTx benefits become ever clearer, how can we capitalize as the world turns to digital health solutions?

10:30 am Virtual Speed Networking & Morning Coffee


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

11:30 am Case Study – Implementation of a Digital Therapeutic During a Pandemic

  • Anil Jina Chief Medical Officer, Akili Interactive


  • Understanding the rationale behind early product launch
  • What does the FDA guidance mean for the industry going forward?
  • Lessons launched along the way since launch

Overcoming the Reimbursement Conundrum

12:00 pm Accelerating Reimbursement During COVID-19 Response


  • Investing time in reimbursement to get your application noticed
  • How COVID-19 has affected the dynamics of DTx reimbursement and what you need to know now
  • What are the major reimbursement considerations you should be prioritizing?

12:20 pm Fireside Chat – How to Unlock Health & Economic Outcomes Through DTx at Scale


  • Why the industry needs to align stakeholder incentives to improve efficacy while lowering cost
  • Detailing a unique example of how this has been done

1:00 pm Virtual Networking Lunch

2:00 pm Panel Discussion – Creating Sustainable, Replicable Models of Reimbursement as a Matter of Priority to Move the Space Forward


  • As leaders shift their attention to sustainable business models, this panel will create a platform for collaboration and problem solving

2:45 pm Panel Discussion – How to Work With Payer, Provider, and Pharma

  • Jin Lee Director of Digital Health Product/Commercial Strategy, Astellas Pharma
  • Kim Baden-Kristensen CEO & Co-Founder, Brain+
  • Seth Feuerstein Executive Director and Founder, Center for Digital Health and Innovation, Yale University School of Medicine


  • How are DTx companies viewed through the eyes of Payers, Providers, and pharma?
  • How to pitch to corporate venture capitalist?
  • What considerations are taken into account in forming commercial partnerships?

Evidence Generation, Clinical Trials & Patient-Centric Development

3:30 pm Role of Evidence in DTx – Current Status and Case Studies


  • Why evidence and value are so intimately connected
  • Has the pandemic forced the issue with value-based contracts?
  • What evidence standards have been set and is this likely to change in the future?

4:00 pm Afternoon Networking Break

4:15 pm The Emergence of Patient-Centric DTx Solutions

  • Amir Lahav Healthcare Intelligence and Digital Transformation Consultant, Mitsubishi Tanabe Pharma America


  • Patient journey should be the primary driving force of DTx design
  • Thinking about patient engagement is key
  • Incorporate Incentivize strategies to ensure adherence
  • Integrated Platforms with medications, apps, and other devices

4:45 pm Patient Fireside Chat – A Different Perspective


  • Aligning interests, breaking down barriers and challenging norms
  • Hearing first-hand the patient experience, patient engagement and opinions on DTx

5:30 pm Roundtable Discussions:


Following the day’s talks and discussions, the audience will split into groups, selecting one of the below topics for
a knowledge exchange session. Each session will last 45 minutes for audience members to discuss:


6:15 pm Chair’s Closing Remarks

6:20 pm End of Day 1